

SENATE No. 1295

The Commonwealth of Massachusetts

PRESENTED BY:

Jason M. Lewis

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act to reduce healthcare costs by promoting non-biased prescriber education.

PETITION OF:

NAME:	DISTRICT/ADDRESS:	
<i>Jason M. Lewis</i>	<i>Fifth Middlesex</i>	
<i>Elizabeth A. Malia</i>	<i>11th Suffolk</i>	<i>2/1/2019</i>
<i>Mark C. Montigny</i>	<i>Second Bristol and Plymouth</i>	<i>2/1/2019</i>
<i>Jonathan Hecht</i>	<i>29th Middlesex</i>	<i>2/1/2019</i>

SENATE No. 1295

By Mr. Lewis, a petition (accompanied by bill, Senate, No. 1295) of Jason M. Lewis, Elizabeth A. Malia, Mark C. Montigny and Jonathan Hecht for legislation to reduce healthcare costs by promoting non-biased prescriber education. Public Health.

[SIMILAR MATTER FILED IN PREVIOUS SESSION
SEE SENATE, NO. 1215 OF 2017-2018.]

The Commonwealth of Massachusetts

**In the One Hundred and Ninety-First General Court
(2019-2020)**

An Act to reduce healthcare costs by promoting non-biased prescriber education.

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:

1 SECTION 1. Section 15A. (a) The commission shall develop, implement and promote an
2 evidence-based outreach and education program to support the therapeutic and cost-effective
3 utilization of prescription drugs for physicians, podiatrists, pharmacists and other health care
4 professionals authorized to prescribe and dispense prescription drugs. In developing the program,
5 the commission shall consult with physicians, podiatrists, pharmacists, nurses, private insurers,
6 hospitals, pharmacy benefit managers, the MassHealth drug utilization review board, the
7 University of Massachusetts medical school and researchers and organizations that are engaged
8 in the development, training and deployment of health practitioner education outreach programs.

9 (b) The program shall arrange for physicians, podiatrists, pharmacists and nurses to
10 conduct face-to-face visits with prescribers, utilizing evidence-based materials and borrowing

11 methods from behavioral science, educational theory and, where appropriate, pharmaceutical
12 industry data and outreach techniques; provided, however, that, to the extent possible, the
13 program shall inform prescribers about drug marketing that is intended to circumvent
14 competition from generic or other therapeutically-equivalent pharmaceutical alternatives or other
15 evidence-based treatment options.

16 The program shall be designed to provide outreach to: physicians, podiatrists and other
17 health care practitioners who participate in MassHealth, the subsidized catastrophic prescription
18 drug insurance program established in section 39 of chapter 19A, other publicly-funded,
19 contracted or subsidized health care programs, academic medical centers and other prescribers.
20 The commission shall, to the extent possible, utilize or incorporate into its program other
21 independent educational resources or models proven effective in promoting high quality,
22 evidenced-based, cost-effective information regarding the effectiveness and safety of
23 prescription drugs including, but not limited to: (i) the Pennsylvania Pharmaceutical Assistance
24 Contract for the Elderly Independent Drug Information Service affiliated with Harvard
25 University; (ii) the Academic Detailing Program through the University of Vermont Larner
26 College of Medicine's Office of Primary Care and Area Health Education Centers Program; (iii)
27 the Drug Effectiveness Review Project coordinated by the Center for Evidence-based Policy at
28 Oregon Health and Science University; and (iv) the North Carolina evidence-based peer-to-peer
29 education program outreach program.

30 (c) The commission shall make an annual report, not later than April 1, on the operation
31 of the program. The report shall be made publicly available on the commission's website and
32 include information on the outreach and education components of the program, revenues,

33 expenditures and balances and savings attributable to the program in health care programs
34 funded by the commonwealth.

35 (d) The commission shall undertake a public education initiative to inform residents of
36 the commonwealth about clinical trials and drug safety information.

37 (e) The commission may establish and collect fees for subscriptions and contracts with
38 private health care payers related to this section. The commission may seek funding from
39 nongovernmental health access foundations and undesignated drug litigation settlement funds
40 associated with pharmaceutical marketing and pricing practices.